VBI Vaccines — SciVac Therapeutics — Merger or Acquisition (November 2015)
17 slides from VBI Vaccines's merger presentation, Nov 5, 2015
Slide 1: SciVac Therapeutics Inc. & VBI Vaccines Inc. Joint Shareholder Call
wll "py, > % S ForLife Z7IMS SciVac Therapeutics Inc. & VBI Vaccines Inc. Joint Shareholder Call \s Ufii\\W 5 November 2015
Slide 2: Important Information for Investors and Stockholders
Important Information for Investors and Stockholders This communication does not constitute an offer to buy or sell or the solicitation of an offer to buy or sell any securities or a solicitation of any vote or approval. This communication relates to the proposed merger between VBI vaccines Inc. (“V
Slide 3: Participants in the Solicitation
Participants in the Solicitation VBI, SciVac, their respective directors and certain of their respective executive officers may be considered participants in the solicitation of proxies in connection with the Proposed Merger. Information about the directors and executive officers of VBI is set forth
Slide 4: Cautionary Statement on Forward-Looking Information
| Cautionary Statement on Forward-Looking Information Certain statements in this communication contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 or under Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securiti
Slide 5: Agenda
Agenda 1. INTRODUCTION 2. | OVERVIEW OF SCIVAC THERAPEUTICS & VBI VACCINES 3. STRATEGIC RATIONALE FOR THE TRANSACTION 4. TRANSACTION DETAILS AS OUTLINED IN THE 8-K & 6-K 5. Q&A \VBINASDAQ: VBIV SCIVACTSX: VAC; OTC: SVACF 5 MIN 10 MIN 10 MIN 5 MIN 15 MIN
Slide 6: About SciVac Therapeutics
ey About SciVac Therapeutics SciVac Therapeutics. (TSX: VAC) is commercial-stage biopharmaceutical company focused on developing improved therapies for the prevention of Hepatitis B SCIVAC OVERVIEW * TSX: VAC (as of 10/26/2015) © Common Stock Currently Outstanding: 757MM Shares © Share Price: $0.185
Slide 7: Sci-B-Vac Technology
Sci-B-Vac™ Technology ONLY COMMERCIAL HBV VACCINE TO MIMIC ALL 3 VIRAL SURFACE ANTIGENS — ALREADY SAFELY USED IN 300,000+ PATIENTS | SCI-B-VAC™ H Mimics all three viral antigens Sci-B-Vac™ ' Achieves: ' Mammalian cell derived vaccines with . i the 3 antigens: © Rapid onset of ' @ Pre-st protection '
Slide 8: About VBI Vaccines
Ming N evoiz About VBI Vaccines gy VBI Vaccines Inc. (NASDAQ: VBIV) is developing novel technologies that seek to expand vaccine protection in significant markets of unmet medical need. VBI OVERVIEW * NASDAQ: VBIV (as at 10/26/2015) Common Stock Currently Outstanding: 23MM Shares Share Price: $2.62
Slide 9: VBI Vaccines Pipeline Platform
VBI Vaccines Pipeline Platform VBI IS DEVELOPING TWO COMPLIMENTARY VACCINE PLATFORM TECHNOLOGIES Enveloped Virus-Like Particle (“eVLP”) PLatform Liquid Particle Vaccine (“LPV™”) Platform + “Third generation” VLP vaccines resemble viruses, + Enables development of vaccines able to withstand but are n
Slide 10: SVT-VBI Synergistic Opportunity
SVT-VBI Synergistic Opportunity Proprietary eVLP & LPV vaccine Multiple product Next-generation, licensed platforms candidates addressi Hepatitis B vaccine large public health needs First in class CMV candidate Existing revenue generation * Strong immunology & biologics formulation expertise Manufac
Slide 11: SVT-VBI Opportunity
ee SVT-VBI Opportunity SYNERGISTIC MERGER CREATES A UNIQUE ASSET PORTFOLIO AND EXPERIENCED MANAGEMENT TEAM Licensed, 3" generation Hepatitis B vaccine initiating discussions with clinical and regulatory bodies to discuss securing additional approvals in key markets and indications Enveloped Virus-Li
Slide 12: SVT-VBI MergeCo Strategic Vision
SS SVT-VBI MergeCo Strategic Vision BECOME A LEADER IN IMMUNOLOGY INNOVATION BY LEVERAGING SVT-VBI ASSETS & CAPABILITIES IN SIGNIFICANT MARKETS WITH HIGH UNMET MEDICAL NEEDS Infectious Disease Target public health Explore combinations with Leverage assets through priorities with high unmet Cancer Im
Slide 13: SVT-VBI Deal Terms
a SVT-VBI Deal Terms As per October 2015 Definitive Merger Agreement Domicile British Columbia MergeCo Name VBI Vaccines Inc. Structure *VBIV will survive the merger as a wholly-owned subsidiary of VAC All outstanding shares of VBIV will be converted into/exchanged for VAC shares as per the followin
Slide 14: Peer Comparison
Peer Comparison SAMPLE OF NASDAQ VACCINE & 10 COMPANIES Company Ticker Date Public Lead Program Dev'tStage Share Price ($U.S.)_ Market Cap ($U.S.) Therapeutic HSV-2 Genocea GNCA Febuary 2014 PReUniGceeeue Phil $6.80 $190.8M A Oncology: solid Immune Design IMDZ July 2014 eee Phi $12.22 $246M. HPV, Ph
Slide 15: Experienced Leadership
Experienced Leadership SVT-VBI’s management and board will bring vaccine discovery, development, financing, and commercialization expertise JEFF BAXTER | PRESIDENT & CEO Mr. Baxter joined VBI in September of 2009. Previously, he was a managing partner of The Column fest] Group, a venture capital fir
Slide 16: Experienced Leadership Cont.
Experienced Leadership Cont. BOARD OF DIRECTORS Dr. Steve Gillis is a Ph.D. immunologist by training with ‘expertise in molecular and tumor immunology. Previously, he served as the Founder and CEO of Corixa, which was acquired in 2005 by GSK for $300M. Prior to Corixa, Dr. Gillis was Founder and Dir
Slide 17: For Life
For Life Curt Lockshin SciVac Therapeutics, Inc Gad Feinstein Rd., P.O. Box 580 Rehovot, Israel 7610303 +972-8-948-0625 [email protected] AW, \ N y svbi- Z S Z/ S Zing Jeff Baxter VBI Vaccines, Inc. 222 Third Street, Suite 2241 Cambridge, MA 02142 (617) 830-3031 [email protected] W7
SciVac Therapeutics — Merger or Acquisition (November 2015) on 6ix